Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand)

Nagoya, Medicine

Material Transfer Agreement (MTA) for the development of novel anti-CD19 and CD37 chimeric antigen receptor T-cells. This collaboration aims to expand the research and development of the treatment for clinical use and to strengthen the collaboration between the universities through a Memorandum of Understanding (MOU).